In ten pages this paper discusses the process of this vaccine and what is required for FDA approval.  Seven sources are cited in the bibliography with the inclusion of two illustrations.
                                    
  
                                    
                                     Name of Research Paper File: MM12_PGprvnr.rtf
                                    
                                    
                                        
                                            
                                                    Unformatted Sample Text from the Research Paper: 
                                                    
                                                
                                                    a couple of illustrations but given the examples, it should be easy for the student to fill in with the other graphics.] Product Life Cycle and Market Demand 	Prevnar is   
                                                
                                                    one of the latest releases from Wyeth Lederle; it is a Pneumococcal Conjugate Vaccine (PCV-7) (CDC, 2001). This vaccine has been shown to be effective in preventing invasive pneumococcal disease   
                                                
                                                    in small children (CDC, 2001). Prior to Wyeths development and release of Prevnar, "pneumococcal infections caused approximately 700 cases of meningitis, 17,000 cases of bacteremia - blood stream infections -   
                                                
                                                    and 200 deaths each year in children under age five" (CDC, 2001). The most severe infection this drug prevents is meningitis (CDC, 2001). Approximately five percent of children under the   
                                                
                                                    age of 5 years who contract pneumococcal meningitis will die of this disease (CDC, 2001). 	Wyeth, formerly named American Home Products (Wyeth, 2002). is a leader in the research and   
                                                
                                                    development of numerous types of health care and medical care products (Wyeth, 2002). The major divisions within the company include: Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health   
                                                
                                                    (Wyeth, 2002). Through its different divisions, the company is involved in discovering, developing, manufacturing and marketing pharmaceuticals, vaccines, biotechnology products and non-prescription medicines (Wyeth, 2002). 	This paper focuses on Prevnar,   
                                                
                                                    which is in the vaccine division. Wyeth manufactures other vaccines, including: * FluShield(r), Influenza Virus Vaccine, which helps to prevent getting influenza;  * Pnu-Imune(r) 23, Pneumococcal Vaccine, which helps   
                                                
                                                    to prevent pneumococcal diseases in adults, such as pneumonia,  * HibTITER(r), Haemophilus b Conjugate Vaccine, which helps to prevent Haemophilus influenzae type b, also known as Hib disease, including   
                                                
                                                    meningitis, in children (Wyeth, nd).  	The Market Portfolio is presented in the following illustration.   Demand Forecast 	The model used and brief explanations for the products in the